Clinical Trial Update: A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial updates the use of subcutaneous tocilizumab as monotherapy or with non-biologic DMARDs in rheumatoid arthritis; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2018-11-13